For Q1 FY2026 ended March 31, 2026, revenue was $147.4M, up 41.2% YoY. Net loss was $2.5M, improving 87.3% from a net loss of $19.6M in the prior year quarter. Operating loss was $6.5M, improving 34.3% YoY. Diluted EPS was -$0.02, improving 90.5% YoY. The company had negative equity of $16.3M and long-term debt of $78.6M.
•Revenue grew 41.2% YoY to $147.4M.
•Net loss narrowed 87.3% to $2.5M.
•Operating loss improved 34.3% to $6.5M.
•Diluted EPS improved to -$0.02 from -$0.21.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
The Oncology Institute, Inc., an oncology company provides various oncology services in the United States. Its business is organized into three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other.
The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services Educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs.
Its portfolio also includes operates combined community clinics and infusion suites, and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. The company serves adult and senior cancer patients. Founded in 2007, The Oncology Institute is headquartered in Cerritos, California.
The Oncology Institute, Inc. is an oncology company that provides a comprehensive range of cancer care services in the United States. Its operations are organized into three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion therapy, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services. Additionally, it provides educational seminars, support groups, counseling services, and 24/7 patient assistance and support. The institute also manages clinical trials and palliative care programs. Its portfolio includes combined community clinics and infusion suites, as well as a specialty pharmacy that dispenses oral and self-injectable medications both in-office and via mail-order for patients undergoing cancer therapies. The company primarily serves adult and senior cancer patients.
Where is The Oncology Institute (TOI) listed and what currency does it trade in?
The Oncology Institute, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol TOI. Its shares are traded in U.S. dollars (USD), reflecting its headquarters and primary operations in the United States. The NasdaqCM is a U.S.-based stock exchange that lists smaller-cap companies, and TOI's listing there provides investors with access to trade its shares in the world's largest equity market.
What sector and industry does The Oncology Institute (TOI) belong to?
The Oncology Institute, Inc. operates in the Healthcare sector, specifically within the Medical Care Facilities industry. This classification indicates that the company is involved in providing medical care services directly to patients, with a focus on oncology. As a medical care facility, it offers a range of cancer treatment and support services, including infusion therapy, radiation, and clinical trials, distinguishing it from pharmaceutical or biotech companies that primarily develop drugs.
Where is The Oncology Institute headquartered and what markets does it serve?
The Oncology Institute, Inc. is headquartered in Cerritos, California, United States. Founded in 2007, the company serves adult and senior cancer patients across the United States. Its services are delivered through combined community clinics and infusion suites, as well as a specialty pharmacy that provides medications via in-office dispensing and mail-order. The company's focus on the U.S. market allows it to cater to a large and growing population of cancer patients, leveraging its integrated care model to offer comprehensive oncology services.
How does The Oncology Institute (TOI) generate revenue?
The Oncology Institute generates revenue through three main segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The Specialty pharmacy segment includes dispensing oral and self-injectable medications to patients, both in-office and via mail-order, which provides a recurring revenue stream. Patient Services encompass physician consultations, in-house infusion therapy, radiation therapy, and outpatient blood product transfusions, which are typically billed to insurers or patients. Clinical Trials & Other includes revenue from managing clinical trials and palliative care programs. By integrating these services under one roof, the company captures multiple revenue sources from each patient, enhancing its financial model.